01 3Exjade
02 6Exjade/Jadenu
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 653
2019 Revenue in Millions : 975
Growth (%) : -33
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 563
2020 Revenue in Millions : 653
Growth (%) : -14
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 323
2021 Revenue in Millions : 563
Growth (%) : -43
Main Therapeutic Indication : Blood Related Disorders
Currency : USD
2014 Revenue in Millions : 3.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 926
2014 Revenue in Millions : 917
Growth (%) : -1%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 956
2015 Revenue in Millions : 917
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,059
2016 Revenue in Millions : 956
Growth (%) : 11
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,099
2017 Revenue in Millions : 1,059
Growth (%) : 4%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 975
2018 Revenue in Millions : 1,099
Growth (%) : -11
LOOKING FOR A SUPPLIER?